MTST (MetaStat) 14-Day RSI: 99.98 (As of Jul. 08, 2026)


What is MetaStat 14-Day RSI?

MetaStat MTST 14-Day RSI is 99.98 as of Jul. 08, 2026.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2026-07-08), MetaStat's 14-Day RSI is 99.98.

The industry rank for MetaStat's 14-Day RSI or its related term are showing as below:

MTST's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 51.235 vs MTST: 99.98

MetaStat  (OTCPK:MTST) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

MetaStat 14-Day RSI Related Terms

MTST vs OBMP, NSPX, ATRX: 14-Day RSI Comparison

For the Biotechnology subindustry, MetaStat's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MetaStat 14-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where MetaStat's 14-Day RSI falls into.


MetaStat  (OTCPK:MTST) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100–[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 14-Day RSI →
What does a 14-Day RSI of 99.98 mean?
MetaStat (MTST) has a 14-Day RSI of 99.98 as of Jul. 08, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on MetaStat and its competitors.
Is MetaStat's 14-Day RSI too high?
MetaStat's current 14-Day RSI is 99.98. The Biotechnology industry median 14-Day RSI is 51.24. MetaStat's value of 99.98 is 95.1% above this industry median.
How does MetaStat's 14-Day RSI compare to OBMP and NSPX?
MetaStat's 14-Day RSI of 99.98 can be compared against companies in the Biotechnology industry. The industry median 14-Day RSI is 51.24. MetaStat's value of 99.98 is 95.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 51.24, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MetaStat's current 14-Day RSI of 99.98 is 95.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on MetaStat and its competitors. For the Biotechnology industry, the median 14-Day RSI is 51.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MetaStat's current 14-Day RSI is 99.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current 14-Day RSI of 99.98. The current 14-Day RSI is 99.98 and 95.1% above the Biotechnology industry median of 51.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For MetaStat (MTST), the current 14-Day RSI is 99.98 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.